We would love to hear your thoughts about our site and services, please take our survey here.
A post on X this morning from the Proff says it all.
AstraZeneca joins KRAS push in cancer with Chinese deal. Preclinical inhibitor sold for 24M with 400M milestone package.
If only more UK small Biotechs were developing preclinical KRAS drugs like @valirxplc 😜 #VAL
Keeping to one’s word…
That’s been my business motto for 39 years and has stood me well up to now.
A few may have to eat humble pie these coming days then another business lesson will kick in, always admit when you are wrong.
Seas inviting so off for a swim.
Adam had this to say on X this morning.
Following the University of Barcelona Evaluation Agreement, this is the second tie-up of #VAL involving a multi-series-based approach. The #VAL preclinical testing pipeline now has a number of oncology arms.
There’s two or three people f ing around with £20/30k making the SP Bob about on quiet days that’s all.
Why do you think they keep stum on large volume days.
They will get wiped out eventually, Val will become to big a company to be toyed with.
Matters not how much shouting goes on here, news comes when it comes, and to be perfectly honest I can’t even guess what the SP will be other than a lot higher than we are.
Even the Proff can put a exact figure on it, need I say more!